- Home
- AUDC vs FHTX Comparison
AUDC vs FHTX Comparison
Compare AUDC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- FHTX
- Stock Information
- Founded
- AUDC 1992
- FHTX 2015
- Country
- AUDC Israel
- FHTX United States
- Employees
- AUDC N/A
- FHTX N/A
- Industry
- AUDC Telecommunications Equipment
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- AUDC Utilities
- FHTX Health Care
- Exchange
- AUDC Nasdaq
- FHTX Nasdaq
- Market Cap
- AUDC 266.8M
- FHTX 517.9M
- IPO Year
- AUDC 1999
- FHTX 2020
- Fundamental
- Price
- AUDC $9.69
- FHTX $7.23
- Analyst Decision
- AUDC Buy
- FHTX Strong Buy
- Analyst Count
- AUDC 2
- FHTX 5
- Target Price
- AUDC $12.00
- FHTX $16.00
- AVG Volume (30 Days)
- AUDC 70.5K
- FHTX 133.0K
- Earning Date
- AUDC 11-06-2024
- FHTX 10-31-2024
- Dividend Yield
- AUDC 3.71%
- FHTX N/A
- EPS Growth
- AUDC 3.49
- FHTX N/A
- EPS
- AUDC 0.45
- FHTX N/A
- Revenue
- AUDC $245,529,000.00
- FHTX $35,185,000.00
- Revenue This Year
- AUDC $1.88
- FHTX N/A
- Revenue Next Year
- AUDC $3.39
- FHTX $15.40
- P/E Ratio
- AUDC $21.55
- FHTX N/A
- Revenue Growth
- AUDC N/A
- FHTX 61.95
- 52 Week Low
- AUDC $7.14
- FHTX $2.70
- 52 Week High
- AUDC $14.45
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- AUDC 51.91
- FHTX 41.45
- Support Level
- AUDC $9.42
- FHTX $7.24
- Resistance Level
- AUDC $9.99
- FHTX $8.35
- Average True Range (ATR)
- AUDC 0.21
- FHTX 0.57
- MACD
- AUDC 0.06
- FHTX -0.08
- Stochastic Oscillator
- AUDC 68.42
- FHTX 16.02
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.